PAR 41.5% 46.0¢ paradigm biopharmaceuticals limited..

Ann: Hay Fever Trial Update, page-13

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 5,518 Posts.
    lightbulb Created with Sketch. 12
    From the announcement;
    "Early indications suggest that the formulation used in the allergic rhinitis clinical trial may need to be optimised"

    These indications are from the field presumably not Paul Rennie or PAR staff. It looks like the solution will be in the formulation.
    I do not know how these tests are designed but may be a better way would be to increase formulation in small numbers till it works. Within safety margins , which if I remember correctly were at least an order of magnitude away from potential harm.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
46.0¢
Change
0.135(41.5%)
Mkt cap ! $82.30M
Open High Low Value Volume
34.0¢ 49.5¢ 34.0¢ $3.506M 8.474M

Buyers (Bids)

No. Vol. Price($)
1 10000 45.5¢
 

Sellers (Offers)

Price($) Vol. No.
46.0¢ 147167 1
View Market Depth
Last trade - 16.10pm 25/11/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.